Robot maker · registered
Johnson & Johnson MedTech (Robotics)
This entry covers only Johnson & Johnson MedTech's surgical robotics program (OTTAVA, MONARCH/MONARCH QUEST, VELYS and the Polyphonic digital ecosystem). Parent-wide Johnson & Johnson financials, headcount and news are out of scope.
OTTAVA uses a unified architecture with four robotic arms integrated directly into the operating table and 'twin motion' synchronized table-arm movement, with instrumentation drawn from Ethicon. MONARCH pairs a physician console with a flexible robotic bronchoscope; the 2025 MONARCH QUEST upgrade adds AI-powered navigation algorithms that raise real-time computational power by 260% and integrates intraoperative 3D imaging via GE HealthCare's OEC 3D CBCT. In March 2025 J&J announced it would use NVIDIA Isaac for Healthcare to accelerate simulation and AI development for its surgical robots, and its Polyphonic digital ecosystem connects planning, intraoperative data and analytics across the portfolio.
Company overview
Identity and operating footprint
Robot models
Specifications remain vendor-claimed
MONARCH Platform (incl. MONARCH QUEST)
- First-to-market robotic-assisted bronchoscopy platform; in the TARGET study clinicians reached small, peripherally located lung nodules in more than 98% of cases with a safety profile comparable to non-robotic techniques
Published multicenter clinical study (TARGET, CHEST Journal) of navigation success and safety
Claim source - MONARCH QUEST (510(k) cleared March 2025) adds AI-powered navigation algorithms increasing real-time computational power by 260% and a verified interface with the GE HealthCare OEC 3D mobile CBCT imaging system
Vendor-stated capabilities of the cleared QUEST navigation upgrade
Claim source
OTTAVA Robotic Surgical System
- General-surgery robotic system with four robotic arms integrated directly into the operating table (unified architecture) and Ethicon-based surgical instrumentation; first clinical cases were Roux-en-Y gastric bypass procedures under an FDA IDE study
Vendor-stated system architecture and first-in-human clinical use in the US IDE trial
Claim source - Met primary safety and performance endpoints in the pivotal IDE bariatric (gastric bypass) study with no conversions reported
Reported pivotal-trial outcome supporting the FDA De Novo submission
Claim source
VELYS Robotic-Assisted Solution
- Robotic-assisted platform for total knee arthroplasty cleared in 20 markets and used in over 55,000 procedures; 510(k) clearance for unicompartmental knee arthroplasty received June 2024
Vendor-stated market clearance and cumulative procedure count at UKA clearance announcement
Claim source
Deployment log
Announced and cited only
Company timeline
Milestones and announcements
Source ledger
7 unique public sources